Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Open Access Gateway

Sleep Quality and Associated Daytime Consequences in Patients with Idiopathic Pulmonary Fibrosis

Mermigkis C.a · Stagaki E.a · Amfilochiou A.a · Polychronopoulos V.a · Korkonikitas P.a · Mermigkis D.a · Bregou M.a · Kouris N.a · Bouros D.b

Author affiliations

aThird Pulmonary Department, Sismanoglion General District Hospital, Athens, and b Department of Pneumonology, Democritus Medical School University of Thrace, Alexandroupolis, Greece

Corresponding Author

Mermigkis Charalampos, MD, PhD

Thrakis 61A

GR–15235 Brilissia, Athens (Greece)

Tel./Fax +30 210 803 4881, E-Mail mermigh@gmail.com

Related Articles for ""

Med Princ Pract 2009;18:10–15

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Objective: The aim of this study was to describe sleep quality and associated daytime consequences in idiopathic pulmonary fibrosis (IPF). Subjects and Methods: Fifteen patients with IPF and 15 control subjects matched on age and anthropometric variables were included in the study. Sleep quality and its daytime consequences were assessed by clinical interview, the Pittsburgh Sleep Quality Index (PSQI), the Functional Outcomes in Sleep Questionnaire (FOSQ), the Fatigue Severity Scale (FSS), the Epworth Sleepiness Scale and attended all-night polysomnography. Results: Polysomnography revealed a decrease in sleep efficiency and slow wave sleep, and an increase in stage 1 sleep and arousal index in IPF patients compared to controls. Daytime tachypnea persisted during sleep. Oxygen saturation below 90% was observed during 34.3 ± 37.3% of the total sleep time (TST). Quality of sleep and daytime function were moderately to significantly impaired based on the PSQI and FOSQ. The total FOSQ score was negatively correlated with TST with oxygen saturation below 90% (p = 0.01, r = –0.62). FSS scores were correlated with TST at oxygen saturation below 90% and mean oxygen saturation during sleep (p = 0.002, r = 0.74, and p = 0.007, r = –0.66, respectively). Conclusions: Our data suggest significant sleep disruption and consequent impairment of physical and social functioning in patients with IPF. In the absence of effective treatments for IPF, the improvement of sleep quality should be a primary therapeutic goal.

© 2008 S. Karger AG, Basel


References

  1. American Thoracic Society/European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classi- fication of the Idiopathic Interstitial Pneu- monias. Am J Respir Crit Care Med 2002;165:277–304.
    External Resources
  2. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646–664.
  3. Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994;150:967–972.
  4. Perez-Padilla R, West P, Lertzman M, Kryger M: Breathing during sleep in patients with interstitial lung disease. Am Rev Respir Dis 1985;132:224–229.
  5. Bye P, Issa F, Berthon-Jones M, Sullivan C: Studies of oxygenation during sleep in patients with interstitial lung disease. Am Rev Respir Dis 1984;129:27–32.
  6. American Academy of Sleep Medicine: Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667–689.
  7. Rechtschaffen A, Kales A: A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles, Brain Information Service/Brain Research Institute University of California at Los Angeles, 1968.
  8. EEG arousals: scoring rules and examples – a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:174–184.
    External Resources
  9. American Academy of Sleep Medicine: International Classification of Sleep Disorders: Diagnostic and Coding Manual, ed 2. Westchester, American Academy of Sleep Medicine, 2005.
  10. American Thoracic Society: Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107–1136.
  11. Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, Lyon K, Smith PL, Schwartz AR, Redline S, Pack AI, Dinges DF: An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997;20:835–843.
  12. Reimer MA, Flemons WW: Quality of life in sleep disorders. Sleep Med Rev 2003;7:335–349.
  13. Gooneratne NS, Weaver TE, Cater JR, Pack FM, Arner HM, Greenberg AS, Pack AI: Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc 2003;51:642–649.
  14. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
  15. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F: Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002;53:737–740.
  16. Carpenter JS, Andrykowski MA: Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 1998;45:5–13.
  17. Johns MW: A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540–545.
  18. Hjollund N, Andersen J, Bech P: Assessment of fatigue in chronic disease: a bibliographic study of fatigue measurement scales. Health Qual Life Outcomes 2007;27:5–12.
  19. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–1123.
  20. Clark M, Cooper B, Singh S, Cooper M, Carr A, Hubbard R: A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001;56:482–486.
  21. Becker HF, Piper AJ, Flynn WE, McNamara SG, Grunstein RR, Peter JH, Sullivan CE: Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med 1999;159:112–118.
  22. Tabachnik E, Muller NL, Bryan AC, Levison H: Changes in ventilation and chest wall mechanics during sleep in normal adolescents. J Appl Physiol 1981;51:557–564.
  23. Millman R, Knight H, Kline LR, Shore ET, Chung DC, Pack AI: Changes in compartmental ventilation in association with eye movements during REM sleep. J Appl Physiol 1988;65:1196–1202.
  24. McNicholas W, Coffey M, Fitzgerald M: Ventilation and gas exchange during sleep in patients with interstitial lung disease. Thorax 1986;41:777–782.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 19, 2008
Accepted: June 01, 2008
Published online: December 04, 2008
Issue release date: December 2008

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: https://www.karger.com/MPP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.